Adaptive Clinical Trial Design
Adaptive Design for Clinical Trials · Also known as: adaptive design, group sequential design, sample size re-estimation, platform trial, Adaptif Klinik Çalışma Tasarımı (Adaptive Design)
Adaptive clinical trial design is a flexible experimental framework, formalised by Bauer and Köhne in 1994, in which pre-specified rules allow the trial to be modified mid-course — adjusting sample size, treatment arms, or randomisation ratios — based on accumulating interim data while rigorously controlling the Type I error rate.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use adaptive design when you expect uncertainty about the effect size at the planning stage and need the flexibility to increase or decrease sample size, drop ineffective arms, or stop early for overwhelming efficacy or clear futility. Four protocol-level assumptions must be pre-specified: adaptation rules must be written into the protocol before any analysis; the Type I error must be controlled via a valid alpha-spending function such as O'Brien–Fleming; the number and timing of interim analyses and the alpha-spending function must be fixed in advance; and blinding of the adaptation decision-making process must be maintained to prevent operational bias.
Strengths & limitations
- Allows ethical early stopping when a treatment is clearly effective or clearly harmful, reducing patient exposure to inferior treatments.
- Sample-size re-estimation prevents the trial from being underpowered due to mis-specified planning assumptions.
- Platform designs enable multiple treatments to be evaluated simultaneously under a single protocol, improving efficiency.
- Regulatory acceptance is established: both the FDA (2019) and EMA have published guidance endorsing pre-specified adaptive designs.
- Substantially more complex to design, execute, and analyse than a fixed-sample trial.
- Requires an independent data monitoring committee (DMC) with strict firewall procedures to preserve blinding.
- Mis-specified adaptation rules or information fractions can inadvertently inflate the Type I error.
- Bias-adjusted estimation at early stopping is non-trivial and may yield wider confidence intervals than a fixed design.
Frequently asked
How does adaptive design differ from ordinary group sequential design?
Group sequential design (e.g. O'Brien–Fleming) allows only pre-specified stopping decisions without changing other aspects of the trial. Adaptive design is broader: it additionally permits mid-trial modifications such as sample-size re-estimation, arm dropping, or ratio changes, provided all rules are pre-specified and a valid combination test or alpha-spending approach controls the overall error rate.
Does peeking at interim data inflate the false-positive rate?
Not if the interim boundaries are derived from a valid alpha-spending function. The function allocates the total alpha (e.g. 0.025 one-sided) across the K looks so that the cumulative probability of a false positive never exceeds the planned level. Un-planned or uncontrolled interim looks do inflate the error rate and are not permitted.
What is sample-size re-estimation and when should I use it?
Sample-size re-estimation is an adaptive rule that adjusts the target enrolment based on observed nuisance parameters (e.g. control-arm event rate or pooled variance) at an interim look. It is used when planning assumptions are uncertain. It does not require unblinding of the treatment effect; blinded re-estimation based on the pooled variance is preferred to avoid operational bias.
Can any trial design be made adaptive?
In principle yes, but the statistical framework differs by outcome type and adaptation type. The rpact package supports group-sequential and adaptive designs for continuous, binary, and survival endpoints. Complex adaptations (biomarker-adaptive enrichment, response-adaptive randomisation) require specialist statistical input and explicit regulatory agreement before the trial begins.
Sources
- Bauer, P. & Köhne, K. (1994). Evaluation of Experiments with Adaptive Interim Analyses. Biometrics, 50(4), 1029–1041. DOI: 10.2307/2533441 ↗
- FDA (2019). Adaptive Design Clinical Trials for Drugs and Biologics — Guidance for Industry. U.S. Food and Drug Administration. link ↗
How to cite this page
ScholarGate. (2026, June 1). Adaptive Design for Clinical Trials. ScholarGate. https://scholargate.app/en/experimental-design/adaptive-design
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Equivalence / Non-Inferiority TrialExperimental design↔ compare
- Randomized Controlled TrialExperimental design↔ compare
- Sequential DesignExperimental design↔ compare